Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
BCL-2 inhibition in AML: an unexpected bonus?
HTML
PDF
Details
Locations
Year:
2018
Type:
review
Source:
Blood
DOI:
10.1182/blood-2018-03-828269
Authors:
Marina Konopleva,
Anthony Letai
Institutions:
The University of Texas MD Anderson Cancer Center,
Dana-Farber Cancer Institute
Language:
English
Topic:
Acute Myeloid Leukemia Research
Subfield:
Hematology
Field:
Medicine
Domain:
Health Sciences
Keywords:
BCL-2 inhibition,
acute myeloid leukemia,
venetoclax,
azacitidine,
decitabine,
low-dose cytarabine,
combination therapy,
duration of response,
myeloid neoplasms
show all 9
SDG:
Good health and well-being
Open Access status:
bronze
Funder:
National Cancer Institute
Award:
Development of Novel Therapeutic Strategies in Human Leukemias
OpenAlex ID:
W2884473318
FWCI:
3.197
Cites:
50
Cited by:
175
Related to:
10